Evidence map›Paper›PMID 29033416›Full record

ArticleInternal medicine (Tokyo, Japan)2018

Progression of Hepatic Hypovascular Nodules with Hypointensity in the Hepatobiliary Phase of Gd-EOB-DTPA-enhanced MRI in Hepatocellular Carcinoma Cases.

Tsukasa Saitoh, Shuichi Sato, Tomotaka Yazaki, Hiroshi Tobita, Tatsuya Miyake, Shunji Ishihara, Takashi Katsube, Hajime Kitagaki, Yoshikazu Kinoshita

Abstract read
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. [Risk analysis for hypervascular transformation of precancerous lesion of hepatocellular carcinoma].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Tsukasa SaitohDepartment of Gastroenterology, Matsue Red Cross Hospital, Japan.
Shuichi SatoDepartment of Internal Medicine II, Shimane University Faculty of Medicine, Japan.
Tomotaka YazakiDepartment of Internal Medicine II, Shimane University Faculty of Medicine, Japan.
Hiroshi TobitaDepartment of Internal Medicine II, Shimane University Faculty of Medicine, Japan.
Tatsuya MiyakeDepartment of Internal Medicine II, Shimane University Faculty of Medicine, Japan.
Shunji IshiharaDepartment of Internal Medicine II, Shimane University Faculty of Medicine, Japan.
Takashi KatsubeDepartment of Radiology, Shimane University Faculty of Medicine, Japan.
Hajime KitagakiDepartment of Radiology, Shimane University Faculty of Medicine, Japan.
Yoshikazu KinoshitaDepartment of Internal Medicine II, Shimane University Faculty of Medicine, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective We investigated the possible factors for predicting the future progression to hepatocellular carcinoma (HCC) from hypovascular nodules detected in the hepatobiliary phase of gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging (Gd-EOB-DTPA-MRI). Methods A total of 91 hypovascular nodules detected by Gd-EOB-DTPA-MRI in 28 patients without any past history of treatment for HCC were retrospectively examined. The nodules were categorized into those with and without HCC progression, then comparisons were made to identify any factors possibly related to a progression to HCC in each case. In addition, we performed a receiver operating characteristics (ROC) analysis to determine the cut-off value for the initial nodule size for predicting HCC progression within 12 months. Results The observation period of the 28 patients was 1,172.6±95.6 (mean±standard error) days. The number of hypovascular nodules that changed to hypervascular ones was 15 (16.5%), and the cumulative incidence of hypervascular transformation was 7.1% at 12 months and 12.7% at 24 months. Of all 91 hypovascular nodules, 33 in 18 patients were diagnosed as HCC based on hypervascular transformation and/or size enlargement, while the remaining 58 did not progress to HCC. There was no significant difference regarding the background characteristics between the HCC progressed and non-progressed groups according to a multivariate analysis, or between the patients who had nodules that progressed to HCC and those with nodules that did not progress to HCC. Regarding HCC progression at 12 months, the area under the ROC (AUROC) had a level of 0.745 and showed that an initial nodule cut-off size of 9.5 mm (sensitivity, 57.9%; specificity, 87.3%) was predictive. Conclusion In patients without a past HCC treatment history, it is difficult to determine whether hypovascular nodules have a high risk of progression to HCC based on background factors alone.

Indexed as

AgedCarcinoma, HepatocellularContrast MediaDisease ProgressionFemaleGadolinium DTPAHumansIncidenceLiver NeoplasmsMagnetic Resonance ImagingMaleMultivariate AnalysisRetrospective StudiesRisk FactorsContrast MediaGadolinium DTPAgadolinium ethoxybenzyl DTPAGd-EOB-DTPAhepatic hypovascular nodulehepatocellular carcinomamagnetic resonance imaging

Identifiers

PMID29033416
PMCPMC5820032

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.